Topical ketorolac tromethamine in the reduction of adverse effects of laser in situ keratomileusist.
JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND = CHOTMAIHET THANGPHAET 2001;
84:804-10. [PMID:
11556458]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
PURPOSE
To evaluate whether topical ketorolac tromethamine can reduce the adverse effect of laser in situ keratomileusis (LASIK).
DESIGN
A prospective randomized controlled clinical study.
PARTICIPANTS
Nineteen patients who underwent bilateral simultaneous LASIK performed at Siriraj Hospital.
INTERVENTION
Patients received two drops of ketorolac tromethamine in one eye immediately after surgery.
MAIN OUTCOME MEASURES
Symptoms of tearing, photophobia, foreign body sensation and pain were evaluated at 30 minutes, 6 hours and 24 hours.
RESULTS
There was no statistically significant difference in symptoms at 30 minutes. At 6 and 24 hours, ketorolac-treated eyes had significantly fewer symptoms compared to non-treated eyes.
CONCLUSIONS
Ketorolac tromethamine reduces some unfavorable symptoms within the first 24 hours after LASIK.
Collapse